Alto Neuroscience (NYSE:ANRO) Trading Down 8% – Here’s What Happened

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price was down 8% during trading on Friday . The stock traded as low as $25.74 and last traded at $25.4310. 45,697 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 340,144 shares. The stock had previously closed at $27.64.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ANRO. Weiss Ratings raised Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. JonesTrading dropped their target price on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a research report on Monday, March 16th. HC Wainwright restated a “buy” rating on shares of Alto Neuroscience in a research report on Wednesday, June 17th. Finally, Wedbush raised their price objective on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Stock Down 5.9%

The business has a 50-day moving average price of $22.83 and a 200-day moving average price of $20.86. The stock has a market cap of $912.23 million, a PE ratio of -10.73 and a beta of 1.04. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, analysts forecast that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ANRO. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Alto Neuroscience by 14,567.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock valued at $3,786,000 after acquiring an additional 211,222 shares during the last quarter. Artia Global Partners LP acquired a new position in Alto Neuroscience in the 4th quarter valued at $520,000. Perceptive Advisors LLC raised its position in shares of Alto Neuroscience by 1,048.5% in the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after buying an additional 1,629,027 shares during the last quarter. 683 Capital Management LLC purchased a new position in Alto Neuroscience in the 4th quarter worth approximately $1,153,000. Finally, Commodore Capital LP purchased a new stake in Alto Neuroscience in the 4th quarter valued at $32,453,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.